MEK kinase-4 inhibitors belong to a specific chemical class of compounds that are designed to target and modulate the activity of the MEK kinase-4 enzyme. MEK kinase-4, also known as MAP2K4, is a crucial component of the mitogen-activated protein kinase (MAPK) signaling pathway, which plays a fundamental role in regulating various cellular processes, including cell proliferation, differentiation, and survival. The inhibitors work by specifically binding to the active site of the MEK kinase-4 enzyme, preventing its normal function and subsequent downstream signaling events. This blockade ultimately leads to the disruption of the MAPK signaling cascade, which can have far-reaching consequences on various cellular activities.
The specific structural features of MEK kinase-4 inhibitors allow them to interact with the enzyme in a highly selective manner, effectively blocking its catalytic function without significantly interfering with other cellular processes or related kinases. By modulating the activity of this kinase, these inhibitors have the potential to influence cellular responses to extracellular signals and contribute to the regulation of cell growth and differentiation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Targets MEK and thereby inhibits the activation of MAPK/ERK. It affects downstream of MAP3K4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Specifically inhibits p38 MAPK. As p38 is downstream of MAP3K4, this inhibitor can indirectly influence its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A selective JNK inhibitor, affecting the JNK pathway that can be activated by MAP3K4. | ||||||
Doramapimod | 285983-48-4 | sc-300502 sc-300502A sc-300502B | 25 mg 50 mg 100 mg | $149.00 $281.00 $459.00 | 2 | |
Targets both p38 MAPK and JNK, influencing pathways downstream of MAP3K4. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
B-Raf inhibitor, although it primarily targets B-Raf mutations, the overall MAPK pathway can be indirectly influenced. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
Inhibits MEK1 and MEK2 and thus has an indirect effect on upstream regulators like MAP3K4. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Another MEK inhibitor, potentially affecting the upstream activity of MAP3K4. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Targets Raf and other kinases, potentially influencing the MAPK pathway. | ||||||
Tipifarnib | 192185-72-1 | sc-364637 | 10 mg | $720.00 | ||
Farnesyltransferase inhibitor that can impact the MAPK pathway, thereby having potential indirect effects on MAP3K4. | ||||||